The Epstein-Barr virus (EBV) is an oncogenic, γ-herpesvirus associated with a broad spectrum 
Introduction
The Epstein-Barr virus (EBV) is a B-cell-lymphotropic, γ-herpesvirus that infects greater than 90% of the world's population. EBV causes infectious mononucleosis (IM) and has a clear association with several lymphoid and epithelial-derived malignancies including Burkitt's lymphomas, Hodgkin's disease, and gastric and nasopharyngeal carcinomas (1) . Following primary infection, the virus establishes lifelong persistance within the host memory B-cell compartment utilizing restricted latent gene expression programs that can manifest as either resting state (Lat I) or cellular immortalization and transformation programs (Lat II, III) (2) (3) (4) (5) . In immune-competent hosts, the outgrowth of EBV-immortalized B cells is prevented through a robust expansion of EBV-specific memory T cells directed toward both lytic and latent antigens (6) . EBV-positive individuals that possess either congenital or acquired immune deficiencies are thus highly susceptible to viral reactivation and malignant transformation. Furthermore, EBVsero-positive patients treated with immune suppressive medications following organ/stem-cell transplantation are at significant risk for developing post-transplant lymphoproliferative disorder (PTLD), an often fatal B-cell lymphoproliferatve disease (LPD) (7) . Current treatment options for these patients are limited, and while chemo/immunotherapeutic reagents can induce tumor remission, these therapies often lead to opportunistic infections and short disease-free survival due to ablation of EBV-specific immunity (8) . Thus, new therapeutic and preventive approaches are needed that specifically target EBV-infected cells while promoting long-term, protective immunity. The development of adoptive cellular therapeutic strategies has proven to be effective (9) (10) (11) ; however, these options have limited availability, are not yet universally applicable, and may be impractical for preventing EBV-associated diseases in solid organ transplant patients. Alternatively, the development of vaccination strategies to enhance primary and recall memory immune responses are becoming increasingly considered as both therapeutic and preventive approaches to EBV-associated diseases including IM (12) (13) (14) (15) .
However, progress in this area has been markedly slow, partly because biomarkers that correlate with host protection are not fully known.
The immediate-early protein BZLF1 is a transcriptional activator that initiates the disruption of latency in EBV-infected cells. Upon expression, BZLF1 binds to the promoters of early EBV lytic genes, triggering a signaling cascade that results in viral DNA replication and virion production (16) (17) (18) (19) . BZLF1 has also been shown to inhibit antiviral cytokine signaling (20, 21) , disrupt CD4 (+) T-cell recognition of MHC-II molecules (22) , and promote B-cell transformation and lymphomagenesis in a humanized NOD/LtSz-scid/IL2Rγ null mouse model of EBV-related disease (23) . Thus, BZLF1 expression is critical for viral activation, persistance, and disease pathogenesis, and, from an immunological standpoint, may represent a prime target of adaptive immune responses. Indeed, BZLF1 is highly immunogenic and elicits robust CD4 (+) and CD8 (+) T-cell responses (6, 24, 25) that dominate the early immune responses in IM patients and produce a healthy pool of EBV-specific memory T cells (26) . Furthermore, we have shown that prevention of EBV-LPD in vivo is associated with the expansion of CD3 (+) CD8 (+) T cells specific for BZLF1 (27) . To the best of our knowledge, the potential therapeutic and preventative effects of BZLF1 vaccination have not been explored.
Here we show that BZLF1 is expressed in EBV-LPD and is capable of eliciting a robust, memory T-cell response in healthy individuals. Furthermore, we demonstrate that presentation of full length BZLF1 by human dendritic cells (DC) promotes the expansion of antigen-specific Tcell immunity and prolongs survival in a humanized, spontaneous murine model of EBV-LPD.
These data suggest that BZLF1 is a critical target protein triggering immunosurveillance of EBV-infected cells and should be considered as a candidate for strategies to develop an EBV vaccine. (1:300) (Santa Cruz) and visualized by immunohistochemistry according to IRB-approved protocol.
ELISPOT assays: Secretion of human interferon-gamma (IFNγ) was detected with the Human IFNγ enzyme-linked immunosorbent spot (ELISPOT) kit (Mabtech) using MultiScreen-HA plates (Millipore, Bedford, MA) as per manufacturer's instructions. Spots were visualized and counted using an Immunospot Imaging Analyzer (Cellular Technology Ltd., Cleveland, OH).
Spot forming units were calculated as the ratio between spots formed in response to antigen stimulation and spots formed in response to anti-CD3 monoclonal antibody (mAb) stimulation.
Mice: Six-week-old C.B.-17 SCID mice were purchased from Taconic Farms (Germantown, Pennsylvania, USA) and housed in a specific pathogen-free environment. Animals showed no evidence of leaky phenotype (28) as determined by murine IgG ELISA (29) . Animal work was approved by The Ohio State University Institutional Animal Care and Use Committee. protein (GMP-grade materials) were purified by a method comprising recovery and washing of inclusion bodies, two gel filtration chromatography steps, and filtration through anion-exchange filters. The identity of rBZLF1 protein was confirmed by mass spectrometry (Nano-LC/MS/MS system). Generation of rAd5F35/BZLF1 virus: The rAd5F35/BZLF1 adenovirus was generated using the Adeno-X expression system 1 (Clontech Laboratories, Inc.). In brief, BZLF1 cDNA was cloned into Not I sites of the mammalian expression cassette pShuttle2. The I-CeuI/PI-SceI fragment containing the BZLF1 expression cassette was gel-purified and subcloned into ICeuI/PI-SceI sites of the AdF35 genome (a gift from Dr. Malcolm Brenner, the Baylor College of Medicine) in which the fiber gene of adenovirus serotype 35 is incorporated into an Ad5 capsid. Finally, Pac-I digested pAd5F35/BZLF1 DNA was used to transfect HEK 293 cells. The individual viral plaque was isolated and positive viral clones were used for large-scale production of rAd5F35/BZLF1 stock. The viral titer was determined using the Adeno-X rapid titer kit (Clontech Laboratories, Inc).
Generation of rAAV2/BZLF1 virus:
The rAAV2/BZLF1 virus consists of rAAV terminal repeats flanking a CMV-IE promoter BZLF1 gene expression cassette. To produce the rAAV2/BZLF1 vector, a Hela-derived cell line containing the above sequences, the AAV rep and cap genes, and a neomycin resistant selectable marker was constructed as described (31) .
The rAAV2/GFP virus is identical to rAAV2/BZLF1 except the GFP gene is driven by the CMV-IE promoter. Large-scale rAAV2 viral preparation, purification, and quantification were performed as described (32) (33) (34) .
In vitro culture and infection of 293T cells:
The human amphotropic-packaging cell line HEK 293T (ATCC®) was maintained in a 37ºC humidified environment supplemented with 5% CO2 in DMEM media containing 5% FBS and grown to 80% confluence prior to infection. Immunoblotting: All immunoblotting was performed as described (35) every seven days thereafter for the duration of the study. Engraftment was confirmed by human IgG ELISA as described (37) . IP vaccination with DCs previously co-cultured with rBZLF1 or control BSA or virally-transduced DCs (described above) began immediately following initial engraftment.
Statistical analyses:
For the comparisons of IFNγ secretion in Figure 2 , Figure 3E , and Figure   5A , two sample t-tests were used. Log-rank tests were used for the survival analyses in Figure 5 and Kaplan-Meier survival curves were generated to display the results. All analyses were performed using SAS/STAT software version 9.2 (SAS Institute Inc., Cary, NC). Figure 3B) . To analyze the ability of rBZLF1 protein to generate BZLF1-specific CTLs, a flow cytometric tetramer assay was used to detect the immunodominant HLA-B8-restricted RAK epitope of the BZLF1 protein (27) . BZLF1-presenting DCs generated RAK-specific CD8 (+) T cells in a dose-dependent fashion ( Figure 3C ). To assess the functional status of these T-cell subsets, we restimulated the DC-PBMC co-cultures at day 13 with autologous LCLs.
Restimulation induced a RAK-specific IFNγ response that was mediated by CD8 To determine whether vaccination with rBZLF1 could prime BZLF1-specific T-cell immunity in vivo, hu-PBL-SCID mice were generated using HLA-B8 (+) PBMCs from a single EBV (+) donor and injected once with either PBS, GM-CSF (5 µg/mouse), rBZLF1 (100 µg/mouse), or rBZLF1 
with GM-CSF as an immune adjuvant (27) . Four weeks post-vaccination, ex vivo splenocytes were re-exposed to rBZLF1-presenting DCs in vitro and assayed for IFNγ secretion by ELISPOT. In comparison to vehicle, vaccination with rBZLF1 alone significantly enhanced BZLF1-specific IFNγ responses (p=0.0007, n=3, Figure 3E) , indicating an efficient expansion of functional, BZLF1-specific T cells. Co-administration of rBZLF1 and GM-CSF did not significantly enhance the effect to BZLF1 re-exposure. expression in malignant cells may provide a mechanism for evading tumor surveillance perhaps by downregulating proinflammatory cytokine signaling (20, 21) or by inhibiting the LMP1-induced upregulation of MHC class I molecules in infected cells (39) . Horizontal EBV transmission to bystander EBV-negative B lymphocytes may also confer a distinct survival advantage to EBV (+) lymphomas by replinishing latently-infected B-cell populations (23) .
Regardless, given the capacity for BZLF1 vaccination to promote EBV-specific immunity and, in turn, delay the progression of fatal EBV-LPD in hu-PBL-SCID mice, it is reasonable to hypothesize that immunosurveillance of BZLF1 by T-cell subsets is a critical factor in the pathogenesis of EBV-LPD and perhaps other associated diseases. Indeed, we have previously shown that prevention of EBV-LPD in hu-PBL-SCID mice treated with combination cytokine therapy is associated with a marked expansion of BZLF1-specific CD8 (+) lymphocytes (27) . 
tumor cells, and is doing so in a chimeric mouse model that is dominated by a dampened human immune response (41) . Indeed, all vaccinated animals in our study ultimately developed fatal EBV-LPD. This effect is likely the result of hypofunctioning human T cells in the xenogeneic environment, the selection of viral antigen-loss mutants that have "hidden" BZLF1 from effector lymphocytes (42) , and/or the presence of natural viral gene polymorphisms (43) that allow for immune escape. The latter possibility would support the rationale to develop a multivalent vaccine that includes additional target antigens covering a broad spectrum of EBV's genetic programs including proteins uniquely associated with malignancy. However, the single valent vaccine utilized in this study might be sufficient to prevent clinically fulminant IM that can occur in genetically susceptible individuals (44) . We are currently exploring multivalent vaccine approaches, including BZLF1 as one of the vaccine immunogens.
Although recombinant BZLF1 vaccination primed BZLF1-specific T-cell responses in vivo, it is particularly interesting that we did not observe an enhanced effect when GM-CSF was administered as an immune adjuvant (Figure 3E) , especially given our prior findings that combination GM-CSF and IL2 therapy protected hu-PBL-SCID mice from fatal EBV-LPD (27) .
Indeed, others have demonstrated that GM-CSF therapy enhances vaccine-mediated immune responses and confers protective immunity in vivo via the induction of professional antigenpresenting cells (45, 46) . In contrast to these observations, however, Serafini and colleagues have shown that high-dose GM-CSF therapy can impair antigen-specific T-cell expansion through the recruitment of myeloid-derived suppressor cells (47) . Thus, in future vaccine studies with BZLF1 it may be useful to assess the delivery of low doses of immune adjuvants that promote specific cellular immunity while limiting the growth and recruitment of suppressor cell subsets. Non-reactive HLA-B8 FLR tetramer was used as a negative control. 
